Trial Profile
Double-Blind, Randomized, Multicenter, Parallel-Group Study to Evaluate the Effects of Pioglitazone on Metabolic Syndrome in Patients With Type 2 Diabetes Treated With Metformin.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Metformin
- Indications Metabolic syndrome; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms PRISMA
- Sponsors Takeda Italia Farmaceutici
- 19 Apr 2013 Primary endpoint 'HDL-cholesterol-level' has been met.
- 25 Oct 2008 New trial record.